Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Legal Officer | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,110 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12 | Direct | 111,251 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 291 | $20.33 | $5,914.75 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,538 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.28 and the highest price at which shares were sold was $20.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,929 | $19.81 | $58,014.12 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,829 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $19.28 and the highest price at which shares were sold was $20.275. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 00:53 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-25-000024 · wk-form4_1738284778.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 2, 2025 22:28 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-25-000002 · wk-form4_1735856926.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,986 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| January 02, 2025 Filed Jan 2, 2025 22:28 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,760 | $19.50 | $112,294.66 |
DisclosureSEC source: 0001549595-25-000002 · wk-form4_1735856926.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,084 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.91 and the highest price at which shares were sold was $19.73. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 02, 2025 Filed Jan 2, 2025 22:28 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-25-000002 · wk-form4_1735856926.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 23:00 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000158 · wk-form4_1733180410.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,746 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 23:00 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,760 | $21.73 | $125,155.01 |
DisclosureSEC source: 0001549595-24-000158 · wk-form4_1733180410.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,084 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.48 and the highest price at which shares were sold was $22.09. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 02, 2024 Filed Dec 2, 2024 23:00 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-24-000158 · wk-form4_1733180410.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 04, 2024 Filed Nov 4, 2024 22:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,290 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001549595-24-000156 · wk-form4_1730760476.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,389 Underlying: Common Stock · 3,290 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024. Read SEC document |
| November 04, 2024 Filed Nov 4, 2024 22:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,290 | $25.00 | $82,250.00 |
DisclosureSEC source: 0001549595-24-000156 · wk-form4_1730760476.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,084 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 04, 2024 Filed Nov 4, 2024 22:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,290 | $9.57 | $31,485.30 |
DisclosureSEC source: 0001549595-24-000156 · wk-form4_1730760476.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 21:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000154 · wk-form4_1730498236.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,506 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 21:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,760 | $24.28 | $139,866.62 |
DisclosureSEC source: 0001549595-24-000154 · wk-form4_1730498236.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,084 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.99 and the highest price at which shares were sold was $24.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 21:57 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-24-000154 · wk-form4_1730498236.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · derivative · entry 7 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,621 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 4,182 | $24.31 | $101,643.51 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,084 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 00:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000146 · wk-form4_1730334601.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 13:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,290 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001549595-24-000133 · wk-form4_1728998177.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,679 Underlying: Common Stock · 3,290 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 13:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 3,290 | $25.00 | $82,250.00 |
DisclosureSEC source: 0001549595-24-000133 · wk-form4_1728998177.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,592 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 14, 2024 Filed Oct 15, 2024 13:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,290 | $9.57 | $31,485.30 |
DisclosureSEC source: 0001549595-24-000133 · wk-form4_1728998177.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,266 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 300 | $22.81 | $6,843.00 |
DisclosureSEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,592 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $22.76 and the highest price at which shares were sold was $22.85. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,460 | $22.19 | $121,174.33 |
DisclosureSEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.75 and the highest price at which shares were sold was $22.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-24-000122 · wk-form4_1727825780.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,290 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,969 Underlying: Common Stock · 3,290 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F5 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,026 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 200 | $25.62 | $5,124.00 |
DisclosureSEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,592 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.50 and the highest price at which shares were sold was $25.74. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 8,850 | $24.93 | $220,611.92 |
DisclosureSEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,792 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $24.46 and the highest price at which shares were sold was $25.41. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,290 | $9.57 | $31,485.30 |
DisclosureSEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 3, 2024 21:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-24-000116 · wk-form4_1725399182.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 22:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,407 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,259 Underlying: Common Stock · 5,407 shares Expires 2030-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The stock option vested as to 1/48 of the total shares monthly beginning June 28, 2020, until the option was fully vested on May 28, 2024. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 22:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,463 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,537 Underlying: Common Stock · 4,463 shares Expires 2029-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The stock option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 22:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 9,870 | $25.01 | $246,842.78 |
DisclosureSEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,592 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $25.00 and the highest price at which shares were sold was $25.14. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 22:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,407 | $9.57 | $51,744.99 |
DisclosureSEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 22:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 4,463 | $1.86 | $8,301.18 |
DisclosureSEC source: 0001549595-24-000114 · wk-form4_1724711007.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,786 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 300 | $22.18 | $6,654.99 |
DisclosureSEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,592 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $22.05 and the highest price at which shares were sold was $22.45. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 5,460 | $21.39 | $116,803.60 |
DisclosureSEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,892 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.94 and the highest price at which shares were sold was $21.75. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| August 01, 2024 Filed Aug 1, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-24-000109 · wk-form4_1722553563.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · derivative · entry 7 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,250 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · derivative · entry 6 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,545 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 2,920 | $20.67 | $60,349.68 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,592 F1 · shares: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.